. . "0"^^ . . . "C\u00EDlem grantov\u00E9ho projektu je na my\u0161\u00EDm modelu lidsk\u00E9ho karcinomu d\u011Blo\u017En\u00EDho \u010D\u00EDpku ovlivnit procesy, kter\u00FDmi n\u00E1dorov\u00E9 bu\u0148ky unikaj\u00ED T bun\u011B\u010Dn\u00E9 imunitn\u00ED odpov\u011Bdi a d\u00E1le vyu\u017E\u00EDt z\u00EDskan\u00E9 poznatky p\u0159i v\u00FDvoji protin\u00E1dorov\u00E9 imunoterapie. Bude studov\u00E1na mo\u017Enost indukce exprese MHC molekul I.t\u0159\u00EDdy na MHC I negativ \u00EDch n\u00E1dorech pomoc\u00ED demethylace DNA. Pro zv\u00FD\u0161en\u00ED schopnosti peptidov\u00FDch a bun\u011B\u010Dn\u00FDch vakc\u00EDn vyvolat silnou T bun\u011B\u010Dnou protin\u00E1dorovou odpov\u011B\u010F budou pou\u017Eita specifick\u00E1 adjuvans (CpG oligonukleotidy \u010Di agonistick\u00E9 protil\u00E1tky proti CD40), kter\u00E1 maj\u00ED schopnost optimalizovat presentaci antigenu dendritick\u00FDmi bu\u0148kami.V experimentech in vitro a in vivo budou d\u00E1le analyzov\u00E1ny mechanismy t\u011Bchto proces\u016F a kone\u010Dn\u00FDm c\u00EDlem bude vyvinout komplexn\u00ED imunoterapeutick\u00E9 protokoly, kter\u00E9 budou \u00FA\u010Dinn\u00E9 p\u0159i terapii n\u011Bkter\u00FDch MHC I negativn\u00EDch n\u00E1dor\u016F a nav\u00EDc, co\u017E je d\u016Fle\u017Eit\u00E9 i z klinick\u00E9ho hlediska, v terapii minim\u00E1ln\u00ED zbytkov\u00E9 choroby po excisi prim\u00E1rn\u00EDho n\u00E1doru.O mo\u017Enostech u\u017Eit\u00ED DNA demethyla\u010Dn\u00EDch" . . . . "13"^^ . . "2007-10-16+02:00"^^ . "13"^^ . . "The goal of the grant project was to influence the mechanisms by which tumour cells are able to evade the immune response, using an animal model for HPV16-associated tumours. The project focused MHC class I-deficient tumours and the experimental therapy"@en . . . . . . . "http://www.isvav.cz/projectDetail.do?rowId=GA301/04/0492"^^ . "Immunotherapy of MHC class I - Tumours: Modulation of the MHC Class I Expression by Demethylation, Selection of Proper Adjuvants"@en . "0"^^ . . . "1"^^ . "Neuvedeno."@en . "In this project, using an animal model resembling human cervical carcinoma associated with human papillomavirus infection, we are investigating possibilities to revert the mechanisms responsible for the tumour escape from T-cell-specific immune response,which are dependent on the expression of MHC class I molecules on tumour cells, and to develop the anti-tumour immunotherapy. We will induce the expression of the MHC class I molecules on MHC class I negative tumour cells by DNA demethylation. Further, we will investigate the capacities of peptide and cellular vaccines, when applied in the context of specific adjuvants (e.g. CpG oligonucleotides and anti-CD40 agonistic antibodies) activating the potential of the dendritic cells to present an antigen, to elicit a strong T-cell-mediated immune response. We will analyze the mechanisms underlying these processes in vitro and in vivo and the goal is to develop a multiple-step immunisation protocol leading to the immunotherapy of selected MHC class I"@en . "C\u00EDlem grantov\u00E9ho projektu bylo na my\u0161\u00EDm modelu pro n\u00E1dory asociovan\u00E9 s\u00A0lidsk\u00FDm papilomavirem ovlivnit procesy, kter\u00FDmi n\u00E1dorov\u00E9 bu\u0148ky mohou uniknout imunitn\u00ED odpov\u011Bdi. Projekt byl zam\u011B\u0159en na problematiku MHC I-deficientn\u00EDch n\u00E1dor\u016F a d\u00E1le na imunoterapii"@cs . . "GA301/04/0492" . . "Imunoterapie MHC I negativn\u00EDch n\u00E1dor\u016F: modulace exprese MHC I demethylac\u00ED a v\u00FDb\u011Br vhodn\u00FDch adjuvans" .